Table 1 Baseline characteristics of the patients, stratified by relapse status

Age (years)

57 (47–63)

57.5 (46.8–64.0)

55.5 (41.3–62.8)

0.660^*

Sex (male)

51 (75)

35 (74)

16 (76)

0.880^**

Time from onset of symptoms to diagnosis (months)

7 (2–23)

6 (1–20)

12 (5–27)

0.081^*

 ≥2

40 (58.8)

24 (51.1)

16 (76.2)

0.045^**

 ≥3

23 (33.8)

13 (27.7)

10 (47.6)

0.112^**

Head and neck involvement

24 (35.3)

17 (36.2)

7 (33.3)

0.821^**

Visceral organ involvement

46 (67.6)

32 (68.1)

14 (66.7)

0.908^**

Allergy history

14 (23.3)

9 (21.95)

5 (26.3)

0.710^**

IgG4-RD RI

9 (6–12)

6 (6–12)

9 (6–12)

0.038^*

Serum IgG4 (g/L)

3.90 (1.44–10.19)

3.09 (1.12–7.26)

7.26 (2.68–18.85)

0.026^*

E (%)

2.05 (0.50–4.25)

2.7 (1.1–4.8)

1.5 (0.4–2.2)

0.074^*

ESR (mm/h)

41 (12–83)

41 (13–82)

42 (10–92)

0.783^*

CRP (mg/L)

6.1 (0.8–31.5)

6.8 (0.73–28.0)

4.97 (0.55–50.2)

0.955^*

Serum IgG (g/L)

16.7 (11.5–22.9)

14.4 (10.9–20.3)

19.9 (15.5–34.3)

0.011^*

Serum IgE (IU/mL)

112 (24–294)

112 (22–260)

119 (25–313)

0.831^*

C3 (g/L)

0.99 (0.80–1.18)

1.02 (0.81–1.21)

0.92 (0.72–1.15)

0.196^*

C4 (g/L)

0.19 (0.13–0.26)

0.23 (0.15–0.27)

0.16 (0.07–0.21)

0.019^*

TG (mmol/L)

1.12 (0.82–1.83)

1.15 (0.94–1.87)

0.90 (0.71–1.54)

0.046^*

TC (mmol/L)

3.71 (3.38-4.52)

4.18 (3.56–4.91)

3.38 (2.82–3.72)

0.005^*

LDL (mmol/L)

2.20 (1.73-2.64)

2.50 (1.98–2.99)

1.92 (1.61–2.27)

0.030^*